|
1.
|
Rubnitz JE, Gibson B and Smith FO: Acute
myeloid leukemia. Hematol Oncol Clin North Am. 24:35–63. 2010.
View Article : Google Scholar
|
|
2.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
3.
|
Harrison CJ, Hills RK, Moorman AV, et al:
Cytogenetics of childhood acute myeloid leukemia: United Kingdom
Medical Research Council Treatment trials AML 10 and 12. J Clin
Oncol. 28:2674–2681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Grimwade D: The clinical significance of
cytogenetic abnormalities in acute myeloid leukaemia. Best Pract
Res Clin Haematol. 14:497–529. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Martin B, Paesmans M, Berghmans T, et al:
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a
systematic review of the literature with meta-analysis. Br J
Cancer. 89:55–64. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Leber B, Lin J and Andrews DW: Still
embedded together binding to membranes regulates Bcl-2 protein
interactions. Oncogene. 29:5221–5230. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Chipuk JE, Moldoveanu T, Llambi F, Parsons
MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Soundararajan S, Chen W, Spicer EK,
Courtenay-Luck N and Fernandes DJ: The nucleolin targeting aptamer
AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer
cells. Cancer Res. 68:2358–2365. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Khor LY, Moughan J, Al-Saleem T, et al:
Bcl-2 and Bax expression predict prostate cancer outcome in men
treated with androgen deprivation and radiotherapy on radiation
therapy oncology group protocol 92-02. Clin Cancer Res.
13:3585–3590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Bender A, Opel D, Naumann I, et al: PI3K
inhibitors prime neuroblastoma cells for chemotherapy by shifting
the balance towards pro-apoptotic Bcl-2 proteins and enhanced
mitochondrial apoptosis. Oncogene. 30:494–503. 2011. View Article : Google Scholar
|
|
12.
|
Guyatt GH, Oxman AD, Vist GE, et al GRADE
Working Group: GRADE: an emerging consensus on rating quality of
evidence and strength of recommendations. BMJ. 336:924–926. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Parmar MK, Torri V and Stewart L:
Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med.
17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Hotta K, Matsuo K, Ueoka H, Kiura K,
Tabata M and Tanimoto M: Meta-analysis of randomized clinical
trials comparing cisplatin to carboplatin in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 22:3852–3859. 2004.
View Article : Google Scholar
|
|
15.
|
Begg CB and Mazumdar M: Operating
characteristics of a rank correlation test for publication bias.
Biometrics. 50:1088–1101. 1994. View
Article : Google Scholar
|
|
16.
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Feng JH, Guo XP, Chen YY, Wang ZJ, Cheng
YP and Tang YM: Prognostic significance of IDH1 mutations in acute
myeloid leukemia: a meta-analysis. Am J Blood Res. 2:254–264.
2012.PubMed/NCBI
|
|
18.
|
Zhao XQ, Li GS, Guo WJ, et al: Expression
of bcl-2 and bax protein and clinical significance in children with
acute leukemia. Chin J Contemp Pediatr. 1:193–195. 1999.(In
Chinese).
|
|
19.
|
Campos L, Rouault JP, Sabido O, et al:
High expression of bcl-2 protein in acute myeloid leukemia cells is
associated with poor response to chemotherapy. Blood. 81:3091–3096.
1993.PubMed/NCBI
|
|
20.
|
Karakas T, Maurer U, Weidmann E, Miething
CC, Hoelzer D and Bergmann L: High expression of bcl-2 mRNA as a
determinant of poor prognosis in acute myeloid leukemia. Ann Oncol.
9:159–165. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Uckun FM, Yang Z, Sather H, et al:
Cellular expression of antiapoptotic BCL-2 oncoprotein in newly
diagnosed childhood acute lymphoblastic leukemia: a Children’s
Cancer Group Study. Blood. 89:3769–3777. 1997.
|
|
22.
|
Maung ZT, MacLean FR, Reid MM, et al: The
relationship between bcl-2 expression and response to chemotherapy
in acute leukaemia. Br J Haematol. 88:105–109. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Fakler M, Loeder S, Vogler M, et al: Small
molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis
in childhood acute leukemia cells and overcome Bcl-2-mediated
resistance. Blood. 113:1710–1722. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Beitinjaneh A, Jang S, Roukoz H and
Majhail NS: Prognostic significance of FLT3 internal tandem
duplication and tyrosine kinase domain mutations in acute
promyelocytic leukemia: a systematic review. Leuk Res. 34:831–836.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Yanada M, Matsuo K, Suzuki T, Kiyoi H and
Naoe T: Prognostic significance of FLT3 internal tandem duplication
and tyrosine kinase domain mutations for acute myeloid leukemia: a
meta-analysis. Leukemia. 19:1345–1349. 2005. View Article : Google Scholar : PubMed/NCBI
|
